C92.A1
BillableAcute myeloid leukemia with multilineage dysplasia, in remission
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C92.A1 an HCC code?
Yes. C92.A1 maps to Metastatic Cancer and Acute Leukemia under the CMS-HCC V28 risk adjustment model (and Metastatic Cancer and Acute Leukemia under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C92.A1
For C92.A1 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C92.A1 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C92.A1 is the ICD-10-CM diagnosis code for acute myeloid leukemia with multilineage dysplasia, in remission. A type of acute myeloid leukemia where multiple cell lines show abnormal development and the cancer has responded to treatment and is in remission. C92.A1 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C92.A1 maps to Metastatic Cancer and Acute Leukemia (HCC 17) with a community, non-dual, aged base RAF weight of 0.368. Under the older V24 model, C92.A1 mapped to the same category but with a base RAF weight of 2.484 — V28 recalibrated weights across the entire model. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Document the multilineage dysplasia findings from the pathology report. Because C92.A1 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C92.A1 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Document the multilineage dysplasia findings from the pathology report
- •Ensure remission status is explicitly documented in the medical record
Clinical Significance
Acute myeloid leukemia with multilineage dysplasia in remission indicates successful treatment response in this typically adverse-prognosis AML subtype. Achieving remission in AML-MLD may require more intensive induction regimens, and many patients are considered for allogeneic stem cell transplantation in first remission given the high relapse risk. The dysplastic features reflect underlying stem cell abnormalities that persist even in morphologic remission.
Documentation Requirements
- ✓Documentation must confirm the AML-MLD diagnosis and explicit remission status with bone marrow showing less than 5% blasts and count recovery.
- ✓Note whether dysplastic features persist in remission bone marrow, as this may indicate residual MDS clone.
- ✓MRD assessment, transplant candidacy evaluation, and post-remission therapy plan must be documented.
- ✓The cytogenetic and molecular risk profile should guide consolidation strategy.
Commonly Confused Codes
- •C92.A0 (AML-MLD not in remission) is for active disease.
- •C92.01 (AML in remission) is less specific and does not capture the multilineage dysplasia.
- •C92.51 (AMML in remission) has monocytic features.
- •D46 codes should not be used during AML remission, even if residual dysplasia is present.
- •Z85.6 (personal history of leukemia) should not be used during active post-remission management.